Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04053764 · ClinicalTrials.gov registry record · Phase 2

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

A Phase 2 study of Sickle Cell Disease (SCD), sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
58
Enrollment target
20
Study locations

NCT04053764 is a Phase 2 study of Sickle Cell Disease (SCD) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 58 participants, below the 400-participant average among 4 other Sickle Cell Disease (SCD) trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04053764, a Phase 2 study of Sickle Cell Disease (SCD), has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
58 participants
Enrollment target
20
Study locations

Study Summary

The goal of the study was to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.

Conditions Studied

Sickle Cell Disease (SCD)

Interventions

  • DRUG Standard of Care
  • DRUG Crizanlizuamb

Study Locations (20)

Other

  • Novartis Investigative Site - Porto Alegre
  • Novartis Investigative Site - Créteil
  • Novartis Investigative Site - Paris
  • Novartis Investigative Site - Athens
  • Novartis Investigative Site - Larissa
  • Novartis Investigative Site - Dublin
  • Novartis Investigative Site - Tripoli
  • Novartis Investigative Site - Amsterdam
  • Novartis Investigative Site - Panama City
  • Novartis Investigative Site - Adana
  • Novartis Investigative Site - Adana

Alabama

  • University of Alabama Birmingham - Birmingham

Illinois

  • University of Illinois Hospital and Health Sciences System . - Chicago

Louisiana

  • Our Lady of the Lake Regional Medic . - Baton Rouge

North Carolina

  • East Carolina University BrodySchool of Med 3 - Greenville

Tennessee

  • Univ of Tenn Health Sciences Ctr - Memphis

Texas

  • University of Texas Health Science Center at Houston - Houston

Rio de Janeiro

  • Novartis Investigative Site - Rio de Janeiro

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2019-12-10
Est. Completion 2023-03-20
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04053764

The ClinicalTrials.gov registry entry for NCT04053764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 400-participant average among 4 other Sickle Cell Disease (SCD) trials with a reported enrollment target (85% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease (SCD) appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT04053764 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Alabama, Illinois.

Frequently Asked Questions

What is clinical trial NCT04053764 about?

NCT04053764 is a clinical study titled "Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease". The goal of the study was to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.

What is the current status of trial NCT04053764?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2019-12-10. Estimated completion is 2023-03-20.

What conditions does trial NCT04053764 study?

This clinical trial studies the following conditions: Sickle Cell Disease (SCD).

What interventions are being tested in trial NCT04053764?

The interventions under investigation include: Standard of Care (DRUG), Crizanlizuamb (DRUG).

Who is sponsoring clinical trial NCT04053764?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04053764 being conducted?

This trial has 20 study locations across Alabama, Illinois, Louisiana, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease (SCD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease (SCD)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.